Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 8;13(18):4522.
doi: 10.3390/cancers13184522.

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Carlo Cattrini  1   2   3 , Rodrigo España  4 , Alessia Mennitto  1   2 , Melissa Bersanelli  5   6 , Elena Castro  7   8 , David Olmos  9   10 , David Lorente  11 , Alessandra Gennari  1   2
Affiliations
Review

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Carlo Cattrini et al. Cancers (Basel). .

Abstract

The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177-PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).

Keywords: LuPSMA; PARP inhibitors; androgen-receptor signaling inhibitors; chemotherapy; ipatasertib; metastatic castration-resistant prostate cancer; metastatic hormone-naïve prostate cancer; metastatic hormone-sensitive prostate cancer; nonmetastatic castration-resistant prostate cancer.

PubMed Disclaimer

Conflict of interest statement

C.C.: expenses from Novartis, Pfizer, Janssen and Ipsen; advisory board from Janssen. M.B.: research funding by Roche S.p.A., Seqirus UK, Pfizer, Novartis, BMS, Astra Zeneca, and Sanofi Genzyme; honoraria as a speaker at scientific events by Bristol-Myers Squibb (BMS), Novartis, Astra Zeneca, Pierre Fabre, and Pfizer; fees as a consultant for advisory role by Novartis, BMS, IPSEN, and Pfizer; fees for copyright transfer by Sciclone Pharmaceuticals. E.C.: honoraria from Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, and Pfizer; consulting or advisory role from Astellas Pharma, Astra Zeneca, Bayer, Janssen, and Merk; research funding from AstraZeneca (Inst), Bayer (Inst), and Janssen (Inst); travel, accommodations, expenses from Astellas Pharma, Astra Zeneca, Bayer, Janssen, and Roche. D.O.: honoraria from Astellas Pharma (Inst), Bayer, and Janssen; consulting or advisory role from AstraZeneca (Inst), Bayer, Bayer (Inst), Clovis Oncology, Janssen, and Janssen (Inst); research funding from Astellas Medivation (Inst), AstraZeneca (Inst), Bayer (Inst), Genentech/Roche (Inst), Janssen (Inst), Pfizer (Inst), and Tokai Pharmaceuticals (Inst); travel, accommodations, expenses from Astellas Pharma, Bayer, Ipsen, and Janssen. D.L.: advisory fees from Sanofi, speaker fees from Janssen, Astellas, Bayer, Sanofi, Pfizer, and BMS, and travel expenses from Janssen and Astellas. A.G.: consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, EISAI, Daichii Sankyo, Speakers Bureau Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, Astra Zeneca, Celgene, and Daichii Sankyo; research funds from EISAI, Eli Lilly, and Roche. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Possible sequencing scenarios in patients with mHSPC initially treated with: (a) Docetaxel; (b) ARSi; (c) Radiotherapy to the primary tumor. Patients with small-cell or neuroendocrine prostate cancer should start a first-line treatment with platinum-based chemotherapy. ARSi: androgen-receptor signaling inhibitors. * Other treatments can include: radium-223 for patients with symptomatic bone metastases; lutetium-177-prostate-specific membrane antigen (PSMA)-617 (LuPSMA) after regulatory approval; olaparib or other PARP-inhibitors for patients with DNA damage and response (DDR) genes defects; pembrolizumab or other immunotherapy for patients with microsatellite instability (MSI)-high/mismatch-deficient prostate cancer; sipuleucel-T (only USA); and mitoxantrone for palliation in symptomatic patients who cannot tolerate other therapies.
See this image and copyright information in PMC

References

    1. Kyriakopoulos C.E., Chen Y.-H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M., Shevrin D.H., Dreicer R., Hussain M., Eisenberger M., et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J. Clin. Oncol. 2018;36:1080–1087. doi: 10.1200/JCO.2017.75.3657. - DOI - PMC - PubMed
    1. Clarke N., Ali A., Ingleby F., Hoyle A., Amos C., Attard G., Brawley C., Calvert J., Chowdhury S., Cook A., et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann. Oncol. 2019;30:1992–2003. doi: 10.1093/annonc/mdz396. - DOI - PMC - PubMed
    1. Cattrini C., Castro E., Lozano R., Zanardi E., Rubagotti A., Boccardo F., Olmos D. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers. 2019;11:1355. doi: 10.3390/cancers11091355. - DOI - PMC - PubMed
    1. Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y., Özgüroglu M., Ye D., Feyerabend S., Protheroe A., et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700. doi: 10.1016/S1470-2045(19)30082-8. - DOI - PubMed
    1. James N., Rush H., Clarke N., Attard G., Cook A., Dearnaley D., Gillessen S., Hoyle A., Jones R., Millman R., et al. 611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) Ann. Oncol. 2020;31:S509. doi: 10.1016/j.annonc.2020.08.871. - DOI